Systems biology and combination therapy in the quest for clinical efficacy
The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
Combinatorial control of biological processes, in which redundancy and multifunctionality are the norm, fundamentally limits the therapeutic index that can be achieved by even the most potent and highly selective drugs. Thus, it will almost certainly be necessary to use new 'targeted' pharmaceuticals in combinations. Multicomponent drugs are standard in cytotoxic chemotherapy, but their development has required arduous empirical testing. However, experimentally validated numerical models should greatly aid in the formulation of new combination therapies, particularly those tailored to the needs of specific patients. This perspective focuses on opportunities and challenges inherent in the application of mathematical modeling and systems approaches to pharmacology, specifically with respect to the idea of achieving combinatorial selectivity through use of multicomponent drugs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Overall, these examples demonstrate the potential use of mechanistic and data driven modelling in dose selection, studies of drug-drug interaction, and identification of the most efficient therapies [338].”
From Cardiovascular disease models: A game changing paradigm in drug discovery and screening (2019) · cites this paper as [338]
In the citing paper
“Accurate predictions of combination treatments from single treatment data would allow a cost-effective pre-selection of promising drug candidates for experimental follow-up, which is highly relevant for modern personalized medicine (Fitzgerald et al., 2006).”
From Efficient Parameter Estimation Enables the Prediction of Drug Response Using a Mechanistic Pan-Cancer Pathway Model (2018) · cites this paper as Fitzgerald et al., 2006
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178
Arzneimittelforschung: Eine Zukunftsoption für Ärzte?
Bethke, T. D. (2012) · Der Pneumologe · doi:10.1007/s10405-012-0601-3 · Cited by 3,261
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561 · cited 1×
“However, growth of cells in the presence of IGF-1 was found to be unaffected when mTOR was inhibited with a rapamycin analog; instead, activity of the upstream regulator Akt increase”
BackgroundRobustness in the Strategy of Scientific Model Building
Box, G. E. P. (1979) · Robustness in Statistics · doi:10.1016/b978-0-12-438150-6.50018-2 · Cited by 1,562
Enzyme and metabolic inhibitors
Webb, J. L. (1963) · Academic Press eBooks · doi:10.5962/bhl.title.7320 · Cited by 1,514
The search for synergy: a critical review from a response surface perspective.
Greco, W. R., Bravo, G., & Parsons, J. C. (1995) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06847-4 · Cited by 1,434
Berenbaum, M. C. (1989) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00026-2 · Cited by 1,414
Cell-signalling dynamics in time and space
Kholodenko, B. N. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1838 · Cited by 1,347 · cited 1×
“However, large models with multiple signaling circuits raise new conceptual issues, such as how best to represent the partitioning of shared components (for example, Ras, MAP kinases and others) among potentially competing pathway”
BackgroundThe tor pathway: a target for cancer therapy
Bjornsti, M.-A., & Houghton, P. J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1362 · Cited by 1,314 · cited 1×
“Inhibition of mTOR is promising as an anticancer strategy, as many proteins lying upstream and downstream of mTOR are deregulated in a human cance”
BackgroundThe TSC1-2 tumor suppressor controls insulin–PI3K signaling via regulation of IRS proteins
Harrington, L. S., Findlay, G. M., Gray, A., Tolkacheva, T., Wigfield, S., Rebholz, H., Barnett, J., Leslie, N. R., Cheng, S., Shepherd, P. R., et al. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200403069 · Cited by 1,123 · cited 1×
“Many growth control circuits also have feedback compensation that makes them self-regulating with respect to inhibition of upstream component”
BackgroundThe Biochemical Basis of an All-or-None Cell Fate Switch in Xenopus Oocytes
Ferrell, J. E., & Machleder, E. M. (1998) · Science · doi:10.1126/science.280.5365.895 · Cited by 1,052
Angeli, D., Ferrell, J. E., & Sontag, E. D. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308265100 · Cited by 1,021
Schoeberl, B., Eichler-Jonsson, C., Gilles, E. D., & Müller, G. (2002) · Nature Biotechnology · doi:10.1038/nbt0402-370 · Cited by 950
Self-citation(1953) · PubMed · Cited by 942
Goldstein, N. I., Prewett, M. C., Zuklys, K., Rockwell, P., & Mendelsohn, J. M. (1995) · PubMed · Cited by 910
Multicomponent therapeutics for networked systems
Keith, C. T., Borisy, A. A., & Stockwell, B. R. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1609 · Cited by 769 · cited 2×
“The combined effect of the rocks and nails can then be found by correctly combining the individual probabilities that an egg will be hit as the union of independent rock and nail events, which after rearrangement results in equation (5).”
BackgroundSirotnak, F. M., Zakowski, M. F., Miller, V. A., Scher, H. I., & Kris, M. G. (2000) · PubMed · Cited by 761
Kholodenko, B. N. (2000) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2000.01197.x · Cited by 643
Bhalla, U. S., Ram, P. T., & Iyengar, R. (2002) · Science · doi:10.1126/science.1068873 · Cited by 631
Systematic discovery of multicomponent therapeutics
Borisy, A. A., Elliott, P. J., Hurst, N. W., Lee, M. S., Lehár, J., Price, E. R., Serbedzija, G., Zimmermann, G. R., Foley, M. A., Stockwell, B. R., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1337088100 · Cited by 620 · cited 1×
“High-throughput screening of drug pairs has sought to systematize and extend the empirical approach as a means of identifying new combination drug”
BackgroundQuantification of Short Term Signaling by the Epidermal Growth Factor Receptor
Kholodenko, B. N., Demin, O. V., Moehren, G., & Hoek, J. B. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.42.30169 · Cited by 618
A three-dimensional model to analyze drug-drug interactions
Prichard, M. N., & Shipman, C. (1990) · Antiviral Research · doi:10.1016/0166-3542(90)90001-n · Cited by 544 · cited 1×
“Debate continues, however, as to which method performs better with noisy clinical data and uncertainty as to therapeutic mechanis”
BackgroundAmino Acid and Insulin Signaling via the mTOR/p70 S6 Kinase Pathway
Tremblay, F., & Marette, A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m106703200 · Cited by 542
Chakravarti, A., Loeffler, J. S., & Dyson, N. J. (2002) · PubMed · Cited by 542
Chou, T.-C., Motzer, R. J., Tong, Y., & Bosl, G. J. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.20.1517 · Cited by 524
Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling
Clarke, R., Liu, M. C., Bouker, K. B., Gu, Z., Lee, R. Y., Zhu, Y., Skaar, T. C., Gomez, B., O'Brien, K., Wang, Y., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1206937 · Cited by 478
Manning, B. D. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200408161 · Cited by 476 · cited 1×
“For example, the phosphatidylinositol-regulated Akt kinase plays a key role in cell survival but also in metabolism and other cellular processe”
BackgroundCriteria for Analyzing Interactions between Biologically Active Agents
(1981) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60912-4 · Cited by 454
(1979) · Elsevier eBooks · doi:10.1016/c2013-0-11050-1 · Cited by 454
Prediction and validation of the distinct dynamics of transient and sustained ERK activation
Sasagawa, S., Ozaki, Y.-I., Fujita, K., & Kuroda, S. (2005) · Nature Cell Biology · doi:10.1038/ncb1233 · Cited by 451
CHOU, T.-C., & TALALAY, P. (2005) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1981.tb06218.x · Cited by 419
The BCR-ABL Story: Bench to Bedside and Back
Wong, S., & Witte, O. N. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104753 · Cited by 399 · cited 1×
“Imatinib (Gleevec), an inhibitor of the bcr-abl oncogene activated in chronic myeloid leukemia (CML), is an outstanding example of a targeted therapeuti”
BackgroundFunctional classification of drugs by properties of their pairwise interactions
Yeh, P., Tschumi, A. I., & Kishony, R. (2006) · Nature Genetics · doi:10.1038/ng1755 · Cited by 350
Chou, T. C., & Talalay, P. (1977) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)39978-7 · Cited by 326
Interaction between cisplatin and gemcitabine in vitro and in vivo.
Peters, G. J., Bergman, A. M., van Haperen, V. W. T. R., Veerman, G., Kuiper, C. M., & Braakhuis, B. J. M. (1995) · PubMed · Cited by 312
Boulikas, T., & Vougiouka, M. (2004) · Oncology Reports · doi:10.3892/or.11.3.559 · Cited by 287
A Biometrics Invited Paper. A Review of Response Surface Methodology from a Biometric Viewpoint
Mead, R., & Pike, D. J. (1975) · Biometrics · doi:10.2307/2529809 · Cited by 283 · cited 1×
“Considerable attention has therefore been devoted to sparse-search strategies that maximize statistical power while minimizing the number of trial”
BackgroundMatar, P., Rojo, F., Cassia, R., Moreno-Bueno, G., Di Cosimo, S., Tabernero, J., Guzmán, M., Rodriguez, S., Arribas, J., Palacios, J., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0870 · Cited by 277 · cited 1×
“The synergism observed in Figure 3f corresponds qualitatively to observations in xenografts for certuximab and gefitinib in combinatio”
ResultAnido, J., Matar, P., Albanell, J., Guzmán, M., Rojo, F., Arribas, J., Averbuch, S. D., & Baselga, J. M. (2003) · PubMed · Cited by 264
A global analysis of cross-talk in a mammalian cellular signalling network
Natarajan, M., Lin, K.-M., Hsueh, R. C., Sternweis, P. C., & Ranganathan, R. (2006) · Nature Cell Biology · doi:10.1038/ncb1418 · Cited by 236
Die quantitativen Probleme der Pharmakologie
Loewe, S. (1928) · Ergebnisse der Physiologie · doi:10.1007/bf02322290 · Cited by 229
Quantitative analysis of signaling networks
Sauro, H. M., & Kholodenko, B. N. (2004) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2004.03.002 · Cited by 217
Manning, B. D., & Cantley, L. C. (2003) · Biochemical Society Transactions · doi:10.1042/bst0310573 · Cited by 210
Control of MAPK signalling: from complexity to what really matters
Hornberg, J. J., Binder, B., Bruggeman, F. J., Schoeberl, B., Heinrich, R., & Westerhoff, H. V. (2005) · Oncogene · doi:10.1038/sj.onc.1208817 · Cited by 199
Self-citationAsthagiri, A. R., & Lauffenburger, D. A. (2001) · Biotechnology Progress · doi:10.1021/bp010009k · Cited by 187
Tools for kinetic modeling of biochemical networks
Alves, R., Antunes, F., & Salvador, A. (2006) · Nature Biotechnology · doi:10.1038/nbt0606-667 · Cited by 181 · cited 1×
“Newly developed software is making it easier to merge small models and perform sophisticated analyses, such as parameter estimation and sensitivity analysi”
MethodTHE CALCULATION OF MICROBIAL ASSAYS
Bliss, C. I. (1956) · Bacteriological Reviews · doi:10.1128/br.20.4.243-258.1956 · Cited by 163
du Manoir, J. M., Francia, G., Man, S., Mossoba, M. E., Medin, J. A., Viloria‐Petit, A., Hicklin, D. J., Emmenegger, U., & Kerbel, R. S. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1109 · Cited by 151
EFFICIENT DESIGNS FOR STUDYING SYNERGISTIC DRUG COMBINATIONS
Tallarida, R. J., Stone, D. J., & Raffa, R. B. (1997) · Life Sciences · doi:10.1016/s0024-3205(97)01030-8 · Cited by 142 · cited 1×
“Considerable attention has therefore been devoted to sparse-search strategies that maximize statistical power while minimizing the number of trial”
BackgroundPrognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing’s sarcoma
Scotlandi, K., Manara, M. C., Hattinger, C. M., Benini, S., Perdichizzi, S., Pasello, M., Bacci, G., Zanella, L., Bertoni, F., Picci, P., et al. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.03.015 · Cited by 132
Camirand, A., Zakikhani, M., Young, F. B. J., & Pollak, M. (2005) · Breast Cancer Research · doi:10.1186/bcr1028 · Cited by 124
Lichtner, R. B., Menrad, A., Sommer, A., Klar, U., & Schneider, M. R. (2001) · PubMed · Cited by 121
Strategic design and three-dimensional analysis of antiviral drug combinations
Prichard, M. N., Prichard, L. E., & Shipman, C. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.3.540 · Cited by 107
Park, C. S., Schneider, I. C., & Haugh, J. M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m304968200 · Cited by 100
A checkerboard method to evaluate interactions between drugs
Martínez-Irujo, J. J., Villahermosa, M. L., Alberdi, E. M., & Santiago, E. (1996) · Biochemical Pharmacology · doi:10.1016/s0006-2952(95)02230-9 · Cited by 90
Data‐Driven Computer Simulation of Human Cancer Cell
CHRISTOPHER, R., DHIMAN, A., FOX, J., GENDELMAN, R., HABERITCHER, T., KAGLE, D., SPIZZ, G., KHALIL, I. G., & HILL, C. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1310.014 · Cited by 83
The Noble Lectures in Immunology
Harboe, M., Møsller, E., Natvig, J. B., & Wigzell, H. (1989) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.1989.tb01179.x · Cited by 71
Tan, M., Fang, H., Tian, G., & Houghton, P. J. (2003) · Statistics in Medicine · doi:10.1002/sim.1467 · Cited by 59 · cited 1×
“Considerable attention has therefore been devoted to sparse-search strategies that maximize statistical power while minimizing the number of trial”
BackgroundTHE CALCULATION OF MICROBIAL ASSAYS
Bliss, C. I. (1956) · Bacteriological Reviews · doi:10.1128/mmbr.20.4.243-258.1956 · Cited by 45
Analysis of the combined effect of two linear inhibitors on a single enzyme
MARTINEZ-IRUJO, J. J., VILLAHERMOSA, M. L., MERCAPIDE, J., CABODEVILLA, J. F., & SANTIAGO, E. (1998) · Biochemical Journal · doi:10.1042/bj3290689 · Cited by 44
Phylogeny and life history evolution of Prodoxus yucca moths (Lepidoptera: Prodoxidae)
Pellmyr, O., Balcázar-Lara, M. A., Althoff, D. M., Segraves, K. A., & Leebens‐Mack, J. (2005) · Systematic Entomology · doi:10.1111/j.1365-3113.2005.00301.x · Cited by 39
Molecular targets and the treatment of myeloid leukemia
Ikeda, A. K., Shankar, D. B., Watanabe, M., Tamanoi, F., Moore, T. B., & Sakamoto, K. M. (2006) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2006.03.011 · Cited by 33 · cited 4×
“(e) Comparison of simulated I1 + I2 combinations with the Loewe additivity curve (calculated by fitting the simulated single inhibitor dose response curves using equation (3) and iteratively solving equation (4) and the Bliss independence curve (generated using the same fitted dose-response curves and applying the eff…”
BackgroundMethodInfluentialStrategies for Multiple Signalling Inhibition
Tortora, G., Bianco, R., & Daniele, G. (2004) · Journal of Chemotherapy · doi:10.1179/joc.2004.16.supplement-1.41 · Cited by 21
van Putte, B. P., Hendriks, J. M., Romijn, S., Pauwels, B., Vermorken, J. B., & Schil, P. E. V. (2005) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2004.07.045 · Cited by 18
Using computational modeling to drive the development of targeted therapeutics.
Nielsen, U. B., & Schoeberl, B. (2005) · PubMed · Cited by 16
Self-citationThomas, H. D., Porter, D. J. T., Bartelink, I. H., Nobbs, J. R., Cole, M. F., Elliott, S., Newell, D. R., Calvert, H., Highley, M., & Boddy, A. V. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2001.01513.x · Cited by 16
Jackson, R. (1993) · PubMed · Cited by 16
Saglio, G. N., Cilloni, D., Rancati, F., & Boano, L. (2004) · PubMed · Cited by 12
Cited by
Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway
Viswanathan, V. S., Ryan, M. J., Dhruv, H. D., Gill, S., Eichhoff, O. M., Seashore-Ludlow, B., Kaffenberger, S. D., Eaton, J. K., Shimada, K., Aguirre, A. J., et al. (2017) · Nature · doi:10.1038/nature23007 · Cited by 2,011
Multi-target-Directed Ligands To Combat Neurodegenerative Diseases
Cavalli, A., Bolognesi, M. L., Minarini, A., Rosini, M., Tumiatti, V., Recanatini, M., & Melchiorre, C. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7009364 · Cited by 1,152
Domingo, E., Sheldon, J., & Perales, C. (2012) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.05023-11 · Cited by 1,009
Synergy and antagonism in natural product extracts: when 1 + 1 does not equal 2
Caesar, L. K., & Cech, N. B. (2019) · Natural Product Reports · doi:10.1039/c9np00011a · Cited by 881
Searching for Drug Synergy in Complex Dose–Response Landscapes Using an Interaction Potency Model
Yadav, B., Wennerberg, K., Aittokallio, T., & Tang, J. (2015) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2015.09.001 · Cited by 845
“…example, aneffective drugcombination maytarget multiple proteinsor pathways that are aberrantly activated in disease, but not in normal cells, and thus reduces the chances that a cancer will develop drug resistance by activating bypassing pathways, when compared to standard mono-therapies [1 – 3].”
Background
Metadata
- Authors
- Fitzgerald, J. B., Schoeberl, B., Nielsen, U. B., & Sorger, P. K.
- Affiliations
- Merrimack Pharmaceuticals (United States) (US)
- Harvard University (US)
- Corresponding author
- Sorger, Peter K
- Venue
- Nature Chemical Biology
- Published
- 2006-08-18
- Volume
- 2
- Issue
- 9
- Pages
- 458-466
- ISSN
- 1552-4450 (ISSN-L)
- 1552-4469
- OpenAlex
- W1994663540
- Cited by
- 570
- References
- 68
- Citations by year
- 2026: 14 · 2025: 15 · 2024: 23 · 2023: 28 · 2022: 30 · 2021: 23 · 2020: 32 · 2019: 36 · 2018: 39 · 2017: 40 · 2016: 45 · 2015: 41 · 2014: 45 · 2013: 34 · 2012: 36
- FWCI
- 12.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Chemical Biology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5p50gm068762-10)
- National Institute of General Medical Sciences (GM 68762)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene Regulatory Network Analysis
- Physical Sciences › Mathematics › Modeling and Simulation › Mathematical Biology Tumor Growth
- Keywords
- combination therapy, systems biology, targeted therapy, therapeutic index, personalized medicine, cytotoxic chemotherapy
- MeSH terms
- Drug Therapy, Combination, Models, Biological, Feedback, Physiological, Systems Biology
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.